1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Venetoclax
Trade Name:
Venclexta
Manufacturer/Distributor:
AbbVie
Classification:
Antineoplastic agent
ATC Class:
L01XX52 - other antineoplastic agent
Status:
active
Notice of Compliance (yyyy/mm/dd):
2016/09/30
Date Marketed in Canada (yyyy/mm/dd):
2016/10/31
Presentation:
Tablet: 10 mg. DIN: 02458039
Tablet: 50 mg. DIN: 02458047
Tablet: 100 mg. DIN: 02458055
Comments:
Venetoclax is indicated as monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least one prior therapy, or patients with CLL without 17p deletion who have received at least one prior therapy and for whom there are no other available treatment options.
It is only available through specialty pharmacies and/or retail oncology pharmacies that are part of AbbVie's managed distribution program.
Back to:
Drug Product Listings 
